| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424930410 | Clostridium | 47 |
| 20080199444 | Composition and method for reducing feces toxins and treating digestive disorders - This invention relates to a method of lowering feces toxin levels and treating digestive disorders (e.g., Irritable Bowel Syndrome or diarrhea) with a composition containing a live beneficial bacterium, a prebiotic, or both. This method includes first identifying a subject in need thereof and then administering to the subject an effective amount of the composition. Also within the scope of this invention is a composition including both a live beneficial bacterium and a prebiotic. | 08-21-2008 |
| 20080254009 | Method of treating gastrointestinal diseases associated with species of genus clostridium - The invention includes a method of treating gastrointestinal diseases associated with species of genus | 10-16-2008 |
| 20080286251 | Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins - Described herein is a microbial composition used to enhance anti-cancer drugs. Specifically, microbial compositions that comprise a part of or an entire microorganism having surface lectins specific to carbohydrate moieties on tumor surface combined with an oncolytic agent. | 11-20-2008 |
| 20080305089 | Pharmaceutical Composition for Protection from Allergies and Inflammatory Disorders - The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of | 12-11-2008 |
| 20090010902 | TLR4 Transcription Activity Suppressor - The object of the invention is to provide a TLR4 transcription factor activity suppressor which suppresses TLR4 transcription factor and is effective in inducing or maintaining remission of ulcerative colitis. | 01-08-2009 |
| 20090053186 | Therapy for primary and metastatic cancers - The present invention relates to compositions and methods for ablating tumor cells in a subject having at least one tumor site. More specifically, the method comprises contacting the tumor cells in at least one tumor with a lytic agent in vivo, under lytic conditions, forming a treated tumor; and applying a sufficient in vivo stimulus to the treated tumor forming a stimulated tumor. Compositions and methods are included for shrinking a local tumor or a distal metastatic tumor, or both in a subject. In a preferred embodiment, the method for shrinking a tumor in a subject comprises: contacting a stimulated tumor cells in vivo with a lytic agent. The stimulus directed toward the tumor cells is capable of increasing the level of chaperone proteins in the tumor cells. The combination of lytic agents and tumor cell stimulus leads to shrinkage of the tumors that were treated directly, wherein the stimulus is either applied simultaneously or sequentially. Moreover, distal or metastatic tumors that were not-treated directly are also decreased by introducing a lytic agents into a stimulated tumor cells in a first-tumor (“the treated tumor” or “the local tumor”). The preferred method steps that include introduction of a lytic agent and stimulation of the tumor cells is repeated in order to maximize the tumor shrinkage effects. | 02-26-2009 |
| 20090257992 | ADJUNCTIVE AGENT FOR LAVAGING THE ALIMENTARY CANAL COMPRISING BUTYRIC ACID BACTERIUM AND/OR LACTIC ACID BACTERIUM - The present invention provides an adjunctive agent for lavaging the alimentary canal which is able to reduce a dose of oral cleaning agent for lavaging the alimentary canal, and is capable of realizing an excellent cleaning effect at the time of use of the aforementioned oral cleaning agent for lavaging the alimentary canal. The means for solving the problem is an adjunctive agent for lavaging the alimentary canal which is comprising butyric acid bacterium (for example, | 10-15-2009 |
| 20090280098 | COMPOSITION FOR BEVERAGE OR FOOD - It is an object of the present invention to provide a composition for a food or beverage containing a butyric acid bacterium which produces butyric acid and is excellent in intestinal regulation and cellooligosaccharide which serves as a substrate for the butyric acid bacterium and facilitates the production of butyric acid, enhancing an amount of butyric acid produced in intestine and being excellent in functions to improve an enteric environment and protect against an infectious disease. That is, the present invention provides a composition for a food or beverage containing a butyric acid bacterium and cellooligosaccharide and having a function to improve an enteric environment and/or a function to protect against an infectious disease, a composition for a food or beverage wherein the butyric acid bacterium is | 11-12-2009 |
| 20100226899 | Categorization of Microbial Communities - The present disclosure provides embodiments of a method for characterizing microbial populations. Exemplified by methods for characterizing microbiota in vaginal samples, the methods provided herein are widely applicable to the characterization of microbial communities. Also provided are probiotic regimens and methods for selecting appropriate probiotic regimens based on the normal vaginal microbiota of a subject. Reagents and kits for detecting normal vaginal microbiota and diagnosing pathogenic microorganisms in the vagina are also provided. | 09-09-2010 |
| 20100316617 | USE OF HYDROGENOTROPHIC ACETOGENIC STRAINS FOR PREVENTING OR TREATING DIGESTIVE DISORDERS - A method of modulating the microbial balance of the digestive ecosystem in a mammal comprising administering to a mammal in need thereof a composition comprising at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain, along with a pharmaceutical and related methods, are described. | 12-16-2010 |
| 20110033431 | TYPE A2 BOTULINUM TOXIN PREPARATION - A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a | 02-10-2011 |
| 20110086011 | Prevention or Treatment of Immune-Relevant Disease by Modification of Microfloral Populations - The present invention is a method for preventing or treating an immune-relevant disease by modulating commensal microbiota populations via antibiotics, exogenous microbiota and/or probiotics. | 04-14-2011 |
| 20110280847 | METHODS AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORE GERMINATION AND OUTGROWTH - Certain bile acids, including novel bile acids, and derivatives thereof can be used to inhibit the germination of | 11-17-2011 |
| 20110311500 | COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS - Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity. | 12-22-2011 |
| 20120020941 | USE OF BLOOD GROUP STATUS III - Provided is a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. Further provided is a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. Further provided is a use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals. | 01-26-2012 |
| 20120058094 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED DISORDERS BY CHARACTERIZING AND RESTORING MAMMALIAN BACTERIAL MICROBIOTA - The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota. | 03-08-2012 |
| 20120207726 | AUTISM-ASSOCIATED BIOMARKERS AND USES THEREOF - The invention discloses biomarkers for human autism. The invention provides methods for treating, preventing, and diagnosing human autism and autism-related disorders. | 08-16-2012 |
| 20120301450 | MIXTURE, DISSOLVING SOLUTION AND PHARMACEUTICAL AGENT EACH COMPRISING THERMOPHILIC MICROORGANISM - To provide a mixture, a dissolving solution and a pharmaceutical agent, which contain a thermophilic microorganism to make it possible to regulate a mucous membrane immune system gene cluster and metabolism-related gene clusters of the intestines and the liver. Each of them is prepared by fermentation of an organic material containing a thermophilic microorganism at a temperature of 50° C. or more and 90° C. or less. By being administered to the animal, it regulates at least one of a mucous membrane immune system gene cluster, a metabolism-related gene cluster in the intestines, and a metabolism-related gene cluster in the liver of the animal. The microorganism includes at least one species of the genus | 11-29-2012 |
| 20130089530 | METHODS AND COMPOSITIONS FOR TREATING PARASITIC WORM INFECTIONS IN A MAMMAL - The invention relates to compositions for treating parasitic worm infections in a mammal. The composition includes an amount of intracellular components of lysed, beneficial, soil-inhabiting yeast cells sufficient to treat parasitic worm infections in a mammal; and/or an amount of whole or lysed soil-inhabiting bacteria cells, wherein the amount is sufficient to treat parasitic worm infections in a mammal, and optionally a pharmaceutically suitable carrier. | 04-11-2013 |
| 20130108598 | METHOD FOR DIAGNOSING RISK OF TYPE 1 DIABETES AND FOR PREVENTING ONSET OF TYPE 1 DIABETES | 05-02-2013 |
| 20130195820 | USE OF BLOOD GROUP STATUS III - The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals. | 08-01-2013 |
| 20130224164 | Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use - Compositions and methods for inhibiting | 08-29-2013 |
| 20130230498 | REDUCING SHORT-CHAIN FATTY ACIDS AND ENERGY UPTAKE IN OBESE HUMANS BY MANAGING THEIR INTESTINAL MICROBIAL COMMUNITIES - The present invention provides for microbial compositions and methods for reducing the concentration of short-chain fatty acids in the gut as a way to reduce energy uptake and manage obesity. More specifically, the invention provides for decreasing short-chain fatty acids available for absorption in the human gut, such as acetate, using one or more of: a probiotic including a homo-acetogenic, acetate oxidizing bacterium that converts acetate to H | 09-05-2013 |
| 20130330307 | FEED ADDITIVE COMPOSITION - A feed additive composition comprising a direct fed microbial in combination with a protease, and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject, which method comprising administering to a subject a direct fed microbial in combination with a protease and a phytase. | 12-12-2013 |
| 20130330308 | FEED ADDITIVE COMPOSITION - A feed additive composition comprising a direct fed microbial (DFM) in combination with a phytase derivable from | 12-12-2013 |
| 20140030241 | NUTRITIONAL COMPOSITIONS FOR INCREASING ARGININE LEVELS AND METHODS OF USING SAME - Nutritional compositions having dietary nucleotides, ω-3 fatty acids and citrulline are provided. The nutritional compositions may be formulated to improve T cell function, increase arginine availability in vivo, regulate myeloid-derived suppressor cells (“MDSC”), and decrease the risk and/or severity of infection after surgery or trauma. Methods of making, using and administering such nutritional compositions to individuals in need of same are also provided. Methods for modulating the affects of MDSC's are also provided. | 01-30-2014 |
| 20140037601 | NUTRITIONAL COMPOSITIONS INCLUDING BRANCHED CHAIN FATTY ACIDS FOR WOUND HEALING - Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. The medical conditions may include wounds, mucositis among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 02-06-2014 |
| 20140037602 | NUTRITIONAL COMPOSITIONS INCLUDING BRANCHED CHAIN FATTY ACIDS AND METHODS OF USING SAME - Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. The medical conditions may include allergies, autoimmune diseases, among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 02-06-2014 |
| 20140037603 | NUTRITIONAL COMPOSITIONS INCLUDING BRANCHED CHAIN FATTY ACIDS FOR IMPROVING GUT BARRIER FUNCTION - Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. Such medical conditions include infection, sepsis, malabsorption, allergy, inflammatory bowel disease, and diarrhea among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 02-06-2014 |
| 20140037604 | NUTRITIONAL COMPOSITIONS COMPRISING ALPHA-HYDROXYISOCAPROIC ACID - Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include α-hydroxyisocaproic acid and may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 02-06-2014 |
| 20140044685 | NUTRITIONAL COMPOSITIONS HAVING ALPHA-HICA AND CITRULLINE - Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include α-hydroxyisocaproic acid and citrulline. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, α-keto-glutarate, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 02-13-2014 |
| 20140056862 | NUTRITIONAL COMPOSITIONS HAVING ALPHA-HICA AND ALPHA-KETOGLUTARATE - Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include α-hydroxyisocaproic acid and α-ketoglutarate. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 02-27-2014 |
| 20140056863 | NUTRITIONAL COMPOSITIONS HAVING ALPHA-HICA AND EICOSAPENTAENOIC ACID - Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include α-hydroxyisocaproic acid eicosapentaenoic acid. It may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, α-ketoglutarate, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 02-27-2014 |
| 20140147425 | SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF - Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human. | 05-29-2014 |
| 20140234279 | FEED ADDITIVE COMPOSITION - A feed additive composition comprising a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject, which method comprising administering to a subject a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase. | 08-21-2014 |
| 20140294787 | EXTENSIONAL VISCOSITY TO PROMOTE SAFE SWALLOWING OF FOOD BOLUSES - Nutritional products having improved cohesiveness of food boluses and methods of making and using same are provided. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products and Trouton ratios of at least 6. Methods of administering such nutritional products to patients having impaired swallowing ability and/or dysphagia are also provided. | 10-02-2014 |
| 20140294788 | METHODS FOR ENHANCING MUSCLE PROTEIN SYNTHESIS FOLLOWING CONCURRENT TRAINING - The present disclosure provides methods for enhancing muscle protein synthesis following physical exertion. In a general embodiment, a method for enhancing muscle protein synthesis following physical exertion is provided and includes administering to an individual a composition comprising from about 15 to about 35 g protein immediately following concurrent training. Programs for enhancing muscle adaptation resulting from concurrent training are also provided. The programs include providing a composition comprising from about 15 to about 35 g protein; and providing guidelines for consumption including a recommendation of the amount of the composition to consume immediately following concurrent training. | 10-02-2014 |
| 20140328813 | Combination Bacteriolytic Therapy for the Treatment of Tumors - Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity. | 11-06-2014 |
| 20150344940 | BIOMARKERS OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION - Embodiments of the invention include methods and/or compositions for analysis of samples for | 12-03-2015 |
| 20160045556 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS - The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of | 02-18-2016 |
| 20160051597 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS - The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of | 02-25-2016 |
| 20160058808 | MICROBE-BASED MODULATION OF SEROTONIN BIOSYNTHESIS - Methods and compositions that can be used to modulate serotonin level in a subject are disclosed herein. In some embodiments, the methods include adjusting the composition of gut microbiota in the subject. Also disclosed are methods of adjusting the level of one or more serotonin-related metabolites to modulate serotonin biosynthesis in a subject, and methods for treating serotonin-related diseases, for example disorders caused by serotonin deficiency. | 03-03-2016 |
| 20160106786 | ENVIRONMENTAL CLOSTRIDIAL BACTERIOTHERAPY AND RELATED FORMULATIONS AND METHODS OF MANUFACTURE AND USE - Compositions and methods for inhibiting | 04-21-2016 |
| 20160151430 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS | 06-02-2016 |
| 20160158294 | Methods of Populating a Gastrointestinal Tract - Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore forming bacteria. Methods include administering an amount effective to engraft and/or augment in the gastrointestinal tract in order to treat or prevent a dysbiosis in the mammalian subject. | 06-09-2016 |
| 20170232044 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS | 08-17-2017 |
| 20170232045 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS | 08-17-2017 |
